Washington University School of Medicine

Home > About Us > Faculty Biographies > Randall Bateman, MD

Randall Bateman, MD

Randall J. Bateman, M.D. is the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine.

Dr. Bateman’s laboratory investigates the causes, and future diagnosis and treatments of Alzheimer's disease utilizing a wide variety of assays and techniques from basic applications, such as quantitative measurement of stable-isotope labeled peptides to clinical translational studies in diagnostic and therapeutic biomarkers for Alzheimer's disease. Dr. Bateman’s lab measures the pathophysiology of Alzheimer's disease in humans and measures amyloid-beta isoform kinetics in Alzheimer's disease. Dr. Bateman trains postdoctoral fellows, graduate students, and undergraduates in his lab.

Dr. Bateman led the development of a technique known as stable isotope-linked kinetics (SILK) that made it possible to determine that clearance of amyloid beta is impaired in patients with Alzheimer’s disease. Bateman and his colleagues are now studying whether alterations in amyloid beta clearance levels can be used to predict Alzheimer’s disease years before symptoms become apparent. Their goal is to prevent damage and loss of brain cells by intervening early in the disease process.

Dr. Bateman is the Director of the Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU) which is launching the first clinical trials in autosomal dominant Alzheimer’s disease (ADAD) aiming to prevent the onset of memory impairment and dementia. Dr. Bateman led efforts to form the first pharma consortium focused on ADAD, the DIAN Pharma Consortium (a collaboration of 10 pharmaceutical companies), and was granted the “largest-ever” Alzheimer’s Association research grant for the DIAN-TU. In 2010, he organized the Autosomal Dominant Alzheimer’s Disease Forum, a patient and family advocacy group for individuals affected by ADAD. Dr. Bateman also serves as the Associate Director and Clinical Core Leader of the DIAN, an international collaboration of leading research centers dedicated to studying ADAD.

Dr. Bateman treats patients with dementia at the Memory Diagnostic Center of Washington University. He is also an investigator for the Charles F. and Joanne Knight Alzheimer’s Disease Research Center and for the Hope Center for Neurological Disorders. He is an inventor of several pending patents and an issued patent, and the scientific co-founding member of C2N Diagnostics, a biotechnology company located at the Center for Emerging Technology in St. Louis.

Dr. Bateman’s honors include the AAN Foundation Corporate Roundtable Clinical Research Fellowship, an American Neurological Association Plenary Session Speaker, a World Technology Award Nominee for Health and Medicine Associate, Scientific American 50 Award recognizing the top 50 scientific achievements of 2006, the Kopolow Award, the 2007 Alzheimer’s Research Forum Community Award, the Beeson Award, the St. Louis Academy of Science Innovator of the Year award, the Co-recipient of the Health Care Heroes in Innovation by the St. Louis Business Journal, the Glenn Award for Research, the 2011 Alzheimer’s Association Zenith Fellows Award, the 2011 Alzheimer’s Research Forum Open Innovation Award, the 2012 MetLife Promising Investigator Award.

His membership in honorary societies includes the American Neurological Association and the American Society for Clinical Investigation Council. Dr. Bateman’s professional memberships include the American Academy of Neurology and the Society for Neuroscience. He serves as an editor and reviewer for many prominent scientific journals and is a sought-after lecturer nationally and internationally.

Medical Training

Dr. Bateman attended Washington University where he received a B.S. degree in Biology (1995) and a B.S. degree in Electrical Engineering (1995). He attended Case Western Reserve University School of Medicine where he received his M.D. (2000) with special emphasis on the neurosciences. He completed a medical internship (2001) at Barnes-Jewish Hospital followed by Neurology residency (2004) at Washington University in St. Louis. He then completed post-doctoral research training with David M. Holtzman, M.D. as mentor and clinical research fellowship training at the Washington University ADRC with John Morris, M.D. as mentor. Dr. Bateman treats patients with dementia at the Memory Diagnostic Center of Washington University.

Selected Publications

Wildsmith KR, Basak JM, Patterson BW, Pyatkivskyy Y, Kim, J, Yarasheski KE, Wang JX, Mawuenyega KG, Jiang H, Parsadanian M, Yoon H, Kasten T, Sigurdson WC, Xiong C, Goate A, Holtzman DM, Bateman RJ. In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. PLoS One 2012; 7(6):e38013. Epub 2012 Jun 4. PMID:22675504; PMCID: PMC3366983

Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367:795-804. PMID:22784036; PMCID: PMC3474597

Huang Y, Potter R, Sigurdson W, Kasten T, Connors R, Morris JC, Benzinger T, Mintun M, Ashwood T, Ferm M, Budd SL, Bateman RJ. Β-Amyloid dynamics in human plasma. Arch Neurol 2012; 69:1591-7. PMID:23229043; PMCID: PMC3808092

Portelius E, Zetterberg H, Dean RA, Marcil A, Bourgeois P, Nutu M, Andreasson U, Siemers E, Mawuenyega KG, Sigurdson WC, May PC, Paul SM, Holtzman DM, Blennow K, Bateman RJ. Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease. J Alzheimers Dis 2012; 31:335-41. PMID:22531418; PMCID: PMC6309706

Mawuenyega KG, Kasten T, Sigurdson W, Bateman RJ. Amyloid-beta Isoform Metabolism Quantitation by Stable Isotope Labeled Kinetics. Anal Biochem 2013; 440:56-62. PMID: 23714261; PMCID: PMC3749773
Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, Yarasheski KE, Holtzman DM, Morris JC, Benzinger TLS, Bateman RJ. Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers. Sci Transl Med 2013; 5, 189ra77 doi: 10.1126/scitranslmed.3005615. PMID: 23761040; PMCID: PMC3838868

Mills SL, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, Martins RN, Masters CM, Mayeux R, McDade E, Morris JC , Oliver A, Ringman JM, Rossor MN, Salloway S, Schofield PR, Snider J, Snyder P, Sperling RA, Stewart C, Thomas RG, Xiong C, Bateman RJ. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Revue Neurologique 2013; 169(10):737-43; PMID: 24016464; PMCID: PMC3880800.
Moulder KL, Snider BJ, Mills SL, Buckles VD, Santacruz AM, Bateman RJ, Morris JC. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther 2013; Oct 17; 5(5):48. [Epub ahead of print]. PMID: 24131566

Benzinger TL, Blazey T, Jack CR Jr, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen PS, Christensen JJ, Ercole L, Hornbeck RC, Farrar AM, Aldea P, Jasielec MS, Owen CJ, Xie X, Mayeux R, Brickman A, McDade E, Klunk W, Mathis CA, Ringman J, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Salloway S, Correia S, Schofield PR, Masters CL, Rowe C, Villemagne VL, Martins R, Ourselin S, Rossor MN, Fox NC, Cash DM, Weiner MW, Holtzman DM, Buckles VD, Moulder K, Morris JC. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci U S A. 2013; Nov 19;110(47):E4502-9. PMID:24194552; PMCID: PMC3839740

Fagan AM, Xiong C, Jasielec M, Bateman RJ, Goate AM, Benzinger TLS, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, Marcus D, Cairns NJ, Buckles VD, Ladenson JH, Morris JC, Holtzman DM. Longitudinal change in CSF biomarkers in Autosomal-Dominant Alzheimer’s disease. Sci Transl Med; 2014; 6:226ra30. PMID: 24598588

Castellano JM, Kim J, Stewart FR, Jiang H, Demattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM. Human apoE Isoforms Differentially Regulate Brain Amyloid- Peptide Clearance. Sci Transl Med. 2011 Jun 29;3(89):89ra57. PMC Journal - In Process. PMID#21715678

Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, Ju Y, Kasten T, Morris JC, Mintun M, Duntley S, Bateman RJ. Effects of Age and Amyloid Deposition on Aβ Dynamics in the Human Central Nervous System. Archives of Neurology. Published online September 12, 2011. doi:10.1001/archneurol.2011.235. NIHMS326112

Zanier ER, Refai D, Zipfel GJ, Zoerle T, Longhi L, Esparza TJ, Spinner ML, Bateman RJ, Brody DL, Stocchetti N. Neurofilament light chain levels in ventricular cerebrospinal fluid after acute aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 2011;82(2):157-9. PMID: 20571038. PMID:20571038

Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimer’s Res Ther. 2011 Jan 6;2(6):35. PMCID: PMC3109410

Hata S, Fujishige S, Araki Y, Taniguchi M, Urakami K, Peskind E, Akatsu H, Araseki M, Yamamoto K, Martins RN, Maeda M, Nishimura M, Levey A, Chung KA, Montine T, Leverenz J, Fagan A, Goate A, Bateman R, Holtzman DM, Yamamoto T, Nakaya T, Gandy S, Suzuki T. Alternative processing of γ-secretase substrates in common forms of mild cognitive impairment and Alzheimer's disease: Evidence for γ-secretase dysfunction. Annals of Neurology 2010; doi: 10.1002/ana.22343. PMID:21681798

Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased Clearance of CNS Amyloid-β in Alzheimer ’s disease. Science December 2010: 330 (6012): 1774.

Cook JJ, Wildsmith KR, Gilberto DB, Holahan MA, Kinney GG, Mathers PD, Michener MS, Price EA, Shearman MS, Simon AJ, Wang JX, Wu G, Yarasheski KE, Bateman RJ. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci 2010;30:6743-50.

Kang J-E, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-Aβ Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle. Science 2009;326:1005-7.

Wildsmith KR, Han B, Bateman RJ. Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry. Analytical Biochemistry 2009;395:116-8.

Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, DeMattos RB, May PC, Paul SM, Holtzman DM. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Annals of Neurology 2009;66:48-54.

Elbert DL, Mawuenyega KG, Scott EA, Wildsmith KR, Bateman RJ. Stable Isotope Labeling Tandem Mass Spectrometry (SILT): Integration with Peptide Identification and Extension to Data-Dependent Scans. J Proteome Res 2008;7:4546-56.

Bateman RJ, Klunk WE. Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Neurotherapeutics 2008;5:381-90.

Bateman RJ, Munsell LY, Chen X, Holtzman DM, Yarasheski KE. Stable Isotope Labeling Tandem Mass Spectrometry (SILT) to Quantify Protein Production and Clearance Rates. Journal of the American Society for Mass Spectrometry 2007;18:997-1006.

Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: Implications for a diagnostic and therapeutic biomarker. Neurology 2007;68:666-9.

Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 2006.

Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006;12:856-61.

WebSanity Top Secret